NFASC and multiple sclerosis: Of significant interest are observations that patients with inflammatory demyelinating disease, such as multiple sclerosis, have high levels of antibodies against both NF186 and NF155 (Mathey et al., 2007; Devaux et al., 2012; Ng et al., 2012) raising the possibility that loss of Neurofascin from established axonal domains contributes to degeneration of myelinated axons overtime as is observed in Actin-CreER;NFfx/− mutants.